checkAd

     972  0 Kommentare Novo Nordisk submits application in the US for including data from the DEVOTE trial in the Tresiba® label - Seite 3




    Lesen Sie auch

    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Novo Nordisk A/S via Globenewswire

    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren
    Seite 3 von 3

    Verfasst von GlobeNewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Novo Nordisk submits application in the US for including data from the DEVOTE trial in the Tresiba® label - Seite 3 Bagsværd, Denmark, 27 May 2017 - Novo Nordisk today announced the submission of a supplemental application to the US Food and Drug Administration (FDA) for including data in the label for Tresiba® (insulin degludec) from the DEVOTE trial, a …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer